Latest News Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination May 05 2026 Latest News Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development Apr 14 2026 Latest News Breakthrough at 2026 AACR! Senhwa Biosciences’ CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy Mar 17 2026 Media Coverage Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development Apr 14 2026 Media Coverage CellType Uses AI to Simulate Human Biology for Drug Discovery Mar 25 2026 Media Coverage Taiwan's Senhwa Biosciences inks immunotherapy deal with US biotech firm CellType Mar 04 2026 Publications Photodynamic activation of CX-5461 enhances its anti-tumor efficacy Apr 03 2026 Publications Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy Jul 11 2025 Publications Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL Mar 27 2025